Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T…

Posted: January 6, 2024 at 2:37 am

Expect to disclose initial SC262 clinical data in 2024 Expect to disclose initial SC262 clinical data in 2024

Excerpt from:
Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T...

Related Posts